GET DAILY SIGNALSAlvotech (ALVO) Q3 2026 Earnings Show Revenue Dip but Clear Signs of Operational Recovery
Key Takeaways
- Alvotech reported third-quarter 2026 total revenue of $111.6 million, down roughly 2% from $113.9 million a year earlier and below analyst consensus estimates.
- Product and service revenue climbed to $58.2 million, up 78% year over year and 6% sequentially, signaling a recovery from the first-half manufacturing slowdown.
- Adjusted EBITDA more than doubled to $31.5 million from $14.4 million in the prior-year quarter.
- The company's nine-month net loss widened to about $140.7 million, compared with a profit of roughly $136.5 million a year earlier, reflecting lower license revenue and one-time items.
- Investors are focused on three pending U.S. Food and Drug Administration (FDA) decisions on biosimilars targeting Simponi, Eylea, and Prolia/Xgeva expected before year-end.
Earnings Context and Why It Matters
Alvotech's third-quarter report arrives as the Icelandic biosimilar developer works to prove its manufacturing turnaround is durable. The first half of 2026 was disrupted by deliberate production slowdowns tied to regulatory remediation, which pressured revenue and pushed the company into quarterly losses. A recovering product line, rising margins, and a stronger adjusted EBITDA figure suggest those operational fixes are beginning to pay off. For investors, the report serves as a key test of whether ALVO can convert its improving supply capacity into sustained growth ahead of pivotal FDA approval decisions expected in the fourth quarter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Alvotech reported total third-quarter 2026 revenue of $111.6 million, slightly below the $113.9 million recorded in the same period last year and short of consensus estimates that ranged from roughly $128 million to $139 million. Within that total, product and service revenue rose 78% year over year to $58.2 million, while license and other revenue declined to $53.2 million from $81.1 million a year earlier.
Adjusted EBITDA improved markedly, reaching $31.5 million compared with $14.4 million in the third quarter of 2025, and adjusted operating profit rose to $20.1 million from $4.1 million. For the first nine months of 2026, total revenue was $323.4 million, down from $420.0 million a year earlier, while adjusted EBITDA increased to $78.3 million from $68.0 million. The company's nine-month net loss widened to approximately $140.7 million, versus a profit of roughly $136.5 million in the prior-year period.
Market Reaction and Investor Sentiment
Sentiment heading into the report was cautious but constructive. Analysts had revised their earnings per share (EPS) estimates lower in the weeks before the release, and the stock has traded well below its average analyst price target, which suggests the market had already priced in a challenging quarter. The revenue shortfall against consensus may weigh on near-term sentiment, but the sharp improvement in adjusted EBITDA and the stronger-than-expected recovery in product revenue could temper downside pressure. Attention now shifts to management's commentary on supply normalization and the timing of pending regulatory decisions. From what I see, this earnings release highlights how ALVO is navigating its transition phase.
Forward Outlook and Key Factors to Monitor
Looking ahead, the central catalyst for Alvotech is a cluster of FDA decisions on biosimilar applications targeting Simponi, Eylea, and Prolia/Xgeva, which are expected before the end of 2026. Approvals could unlock new U.S. market launches and meaningfully expand the company's commercial opportunity.
Investors should also monitor whether the improvement in product revenue and adjusted EBITDA continues into the fourth quarter. Alvotech has reaffirmed full-year 2026 revenue guidance in the range of $650 million to $700 million, alongside an adjusted EBITDA target of $180 million to $220 million. Delivering on that range will require a strong finish to the year as manufacturing capacity normalizes.
Margin trends, license revenue timing, and the pace of supply ramp-up remain important variables. Because license and other revenue can be lumpy from quarter to quarter, the trajectory of product and service revenue is likely to be the clearest signal of underlying demand. Regulatory outcomes, execution on new launches, and cash generation toward the company's positive free-cash-flow goal are all key factors to watch in the coming quarters. I’m watching this closely as the FDA timelines approach.
Using Tickeron’s AI Screener for Deeper Analysis
In my view, tools like Tickeron’s AI Screener help cut through the noise when evaluating companies like ALVO amid earnings volatility. It allows filtering by fundamentals, technical patterns, and industry peers to identify comparable setups more efficiently than manual reviews alone. One thing that stands out is how this kind of screening can surface context on margin trends or sector performance that might otherwise be missed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALVO's RSI Indicator ascending out of oversold territory
The RSI Oscillator for ALVO moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 27 of the 34 cases the stock moved higher. This puts the odds of a move higher at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 64 cases where ALVO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ALVO as a result. In 66 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for ALVO just turned positive on November 10, 2026. Looking at past instances where ALVO's MACD turned positive, the stock continued to rise in 34 of 48 cases over the following month. The odds of a continued upward trend are 71%.
Following a +4.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALVO advanced for three days, in 199 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
ALVO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALVO crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for ALVO entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.057) is normal, around the industry mean (6.379). P/E Ratio (-7.839) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement